TrialCancer science2023

Dual targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: A phase 2 trial.

Xianhua Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.